Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity
- PMID: 1846923
- DOI: 10.1021/jm00105a017
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity
Abstract
Water-soluble analogues of the antitumor alkaloid camptothecin (1) were prepared in which aminoalkyl groups were introduced into ring A or B. Most of the analogues were prepared by oxidation of camptothecin to 10-hydroxycamptothecin (2) followed by a Mannich reaction to give N-substituted 9-(aminomethyl)-10-hydroxycamptothecins (4-12) or by subsequent modification of Mannich product 4 (13, 15, 17, 19, 21). Others were obtained by modification of the hydroxyl group of 2 (25,26) or by total synthesis (35,42,43). These analogues, as well as some of their synthetic precursors, were evaluated for inhibition of topoisomerase I, cytotoxicity, and antitumor activity. Although there was not a quantitative correlation between these assays, compounds that inhibited topoisomerase I were also cytotoxic and demonstrated antitumor activity in vivo. Further evaluation of the most active water-soluble analogue led to the selection of 9-[(dimethylamino)methyl]-10-hydroxycamptothecin (4, SK&F 104864) for development as an antitumor agent. In addition to its water solubility, ease of synthesis from natural camptothecin, and high potency, 4 demonstrated broad-spectrum activity in preclinical tumor models and is currently undergoing Phase I clinical trials in cancer patients.
Similar articles
-
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.Cancer Res. 1995 Feb 1;55(3):603-9. Cancer Res. 1995. PMID: 7834631
-
Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues.J Med Chem. 1998 Jun 18;41(13):2308-18. doi: 10.1021/jm970765q. J Med Chem. 1998. PMID: 9632364
-
Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity.J Med Chem. 1989 Mar;32(3):715-20. doi: 10.1021/jm00123a038. J Med Chem. 1989. PMID: 2537428
-
Camptothecin: current perspectives.Bioorg Med Chem. 2004 Apr 1;12(7):1585-604. doi: 10.1016/j.bmc.2003.11.036. Bioorg Med Chem. 2004. PMID: 15028252 Review.
-
Animal models for studying the action of topoisomerase I targeted drugs.Biochim Biophys Acta. 1998 Oct 1;1400(1-3):301-19. doi: 10.1016/s0167-4781(98)00143-2. Biochim Biophys Acta. 1998. PMID: 9748639 Review.
Cited by
-
Camptothecin delivery methods.Pharm Res. 2002 Oct;19(10):1389-99. doi: 10.1023/a:1020427227285. Pharm Res. 2002. PMID: 12425455 Review.
-
Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania.Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3726-30. doi: 10.1073/pnas.92.9.3726. Proc Natl Acad Sci U S A. 1995. PMID: 7731973 Free PMC article.
-
Camptothecin and its derivatives: Advancements, mechanisms and clinical potential in cancer therapy.Med Oncol. 2024 Oct 9;41(11):263. doi: 10.1007/s12032-024-02527-x. Med Oncol. 2024. PMID: 39382779 Review.
-
Natural products as leads to anticancer drugs.Clin Transl Oncol. 2007 Dec;9(12):767-76. doi: 10.1007/s12094-007-0138-9. Clin Transl Oncol. 2007. PMID: 18158980 Review.
-
Development of an enzyme‑linked immunosorbent assay for camptothecin.Mol Med Rep. 2019 Aug;20(2):959-966. doi: 10.3892/mmr.2019.10342. Epub 2019 Jun 5. Mol Med Rep. 2019. PMID: 31173229 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources